Expression and Immune Effect Study of Therapeutic Recombinant Protein Vaccine VP22Δ-mE6Δ/mE7

China Biotechnology

2009, Vol. 29

Issue (04): 6-11 DOI:

Expression and Immune Effect Study of Therapeutic Recombinant Protein Vaccine VP22Δ-mE6Δ/mE7

Download:

HTML

PDF(607KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract In order to investigate the biological effects of the VP22Δ-mE6Δ/mE7 built in adjuvant fusion protein vaccine on the tumor associated with HPV-16 infection.HSV-1 VP22Δ and HPV-16 mE6Δ/mE7 genes were cloned,and the pET28a-VP22Δ-mE6Δ/mE7 recombinat prokaryotic expression vector was constructed.Vector was transformed into Rosetta(DE3)E.coli string and expressed under the induction of IPTG.The re-naturalized protein was then purified via Ni2+ affinity adsorbent column and identified by SDS-PAGE and Western blot.Purified protein was immunized BalB/C and C57BL/6 mice to evaluate the immunogenicity and anti-tumor activity.The expressed recombinant protein formed as inclusion body with a prediction MW about 34kDa and contained approximately 45% of total somatic protein.The VP22Δ-mE6Δ/mE7 immunization induced higher titer of specific IgG against HPV,higher level of lymphocyte proliferation and better effect on suppressing HPV16 positive TC-1 tumor growth than the mice immunized with mE6Δ/mE7 alone.The results showed that the recombined built-in adjuvant vaccine could induce specific cellular immune response in vitro and inhibit the TC-1 tumor proliferation in vivo,that would be a foundation for further studies and developments of inner adjuvant vaccines.

Key words： HPV-16;recombinant protein vaccine;built-in adjuvant;VP22△;mE6△/mE7

Received: 27 October 2008 Published: 27 April 2009

ZTFLH:

Q786

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GAO Dan-Dan- Bang-Zheng-Hua- Yang-Xu- Bi-Xing-Wei- Li-Zhi-Hua- Ji-Qiu-Pan- Li-Jian-Fang- Li-Jian-Feng- Xu-Wei-Meng

Cite this article:

GAO Dan-Dan- Bang-Zheng-Hua- Yang-Xu- Bi-Xing-Wei- Li-Zhi-Hua- Ji-Qiu-Pan- Li-Jian-Fang- Li-Jian-Feng- Xu-Wei-Meng. Expression and Immune Effect Study of Therapeutic Recombinant Protein Vaccine VP22Δ-mE6Δ/mE7. China Biotechnology, 2009, 29(04): 6-11.

URL:

https://manu60.magtech.com.cn/biotech/ OR https://manu60.magtech.com.cn/biotech/Y2009/V29/I04/6

［1］ Matsha T,Erasmus R,Kafuko A B,et al.Human papillomavirus associated with oesophageal cancer.J Clin Pathol,2002,55:587~590 ［2］ Zur Hausen H.Papillomaviruses and cancer: from basic studies to clinical application.Nat Rev Cancer,2002,2:342~350 ［3］ Baez A,Almodovar J I,Cantor A,et al.High frequency of HPV16associated head and neck squamous cell carcinoma in the Puerto Rican population.Head Neck,2004,26:778~784 ［4］ Wu Q J,Guo M,Lu Z M,et al.Detection of human papillomavirus16 in ovarian malignancy.Br J Cancer,2003,89:672~675 ［5］ Shehata B M,Otto K J,Sobol S E,et al.E6 and E7 oncogene expression by human papilloma virus (HPV) and the aggressive behavior of recurrent laryngeal papillomatosis (RLP).Pediatr Dev Pathol,2008,11:118~121 ［6］ Yan J,Reichenbach D K,Corbitt N,et al.Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen.Vaccine,2009,27:431~440 ［7］ Nindl I,Rindfleisch K,Lotz B,et al.Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology,cervical intraepithelial neoplasia and cervical cancer.Int J Cancer,1999,82:203~207 ［8］ Roden R B,Ling M,Wu T C.Vaccination to prevent and treat cervical cancer.Hum Pathol,2004,35:971~982 ［9］ Cheng W F,Hung C H,Chai C Y,et al.Enhancement of sindbis virus selfreplicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen.J Virol,2001,75:2368~2376 ［10］ Oliveira S C,Harms J S,Afonso R R,et al.A genetic immunization adjuvant system based on BVP22antigen fusion.Hum Gene Ther,2001,12:1353~1359 ［11］ Qian X,Lu Y,Liu Q,et al.Prophylactic,therapeutic and antimetastatic effects of an HPV16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model.Immunol Lett,2006,102:191~201 ［12］ Franceschi S.The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer.Recent Results Cancer Res,2005,166:277~297 ［13］ Villa L L.Overview of the clinical development and results of a quadrivalent HPV (types 6,11,16,18) vaccine.Int J Infect Dis,2007,11 Suppl 2:S17~25 ［14］ Vambutas A,DeVoti J,Nouri M,et al.Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virusinduced lesions and latently infected sites in a preclinical cottontail rabbit papillomavirus model.Vaccine,2005,23:5271~5280 ［15］ Ohlschlager P,Pes M,Osen W,et al.An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV16 E7SH) induces an E7 wildtypespecific T cell response.Vaccine,2006,24:2880~2893 ［16］ Brinkman J A,Xu X,Kast W M.The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV16 induced tumors.Vaccine,2007,25:3437~3444 ［17］ Mouzakitis G,McLauchlan J,Barreca C,et al.Characterization of VP22 in herpes simplex virusinfected cells.J Virol,2005,79:12185~12198 ［18］ Duffy C,Mbong E F,Baines J D.VP22 of herpes simplex virus 1 promotes protein synthesis at late times in infection and accumulation of a subset of viral mRNAs at early times in infection.J Virol,2009,83:1009~1017 ［19］ Schwarze S R,Hruska K A,Dowdy S F.Protein transduction: unrestricted delivery into all cells? Trends Cell Biol,2000,10:290~295 ［20］ Bennett R P,Dalby B,Guy P M.Protein delivery using VP22.Nat Biotechnol,2002,20:20

No related articles found!

Viewed

Full text

Abstract

Cited

Shared

Discussed